Search research articles
Contact Us
Filters
Showing results (41-50 of 59) with videos related to
Page
of 6
Sort By:
Trials
|
July 28, 2012
What is the role and authority of gatekeepers in cluster randomized trials in health research?
Antonio Gallo, Charles Weijer, Angela White, et al.
Regulatory Toxicology and Pharmacology : RTP
|
October 25, 2025
Impurity qualification requirements for drug-linkers related impurities used to generate antibody-drug conjugates
Osama Chahrour, Paul D Cornwell, Penny Leavitt, et al.
Journal of Medical Internet Research
|
October 8, 2020
Experiences of Serving and Ex-Serving Members With the PTSD Coach Australia App: Mixed Methods Study
Jane Shakespeare-Finch, Karolina K Alichniewicz, Esben Strodl, et al.
Trials
|
July 28, 2011
Who is the research subject in cluster randomized trials in health research?
Andrew D McRae, Charles Weijer, Ariella Binik, et al.
Internet Interventions
|
September 17, 2020
Clinicians' perceptions of PTSD Coach Australia
Esben Strodl, Jane Shakespeare-Finch, Karolina K Alichniewicz, et al.
Regulatory Toxicology and Pharmacology : RTP
|
April 16, 2021
Use of less-than-lifetime (LTL) durational limits for nitrosamines: Case study of N-Nitrosodiethylamine (NDEA)
Joel P Bercu, Melisa Masuda-Herrera, George Johnson, et al.
Regulatory Toxicology and Pharmacology : RTP
|
August 7, 2021
Calculating qualified non-mutagenic impurity levels: Harmonization of approaches
Jessica C Graham, Mark W Powley, Erika Udovic, et al.
Regulatory Toxicology and Pharmacology : RTP
|
July 11, 2025
Evaluating the lifetime cumulative dose as a basis for carcinogenic potency of nitrosamines - a key tenet underpinning less-than-lifetime approaches for establishing acceptable intake limits
Susan P Felter, Ashley M Mudd, David J Ponting, et al.
Regulatory Toxicology and Pharmacology : RTP
|
March 28, 2018
Making reliable negative predictions of human skin sensitisation using an in silico fragmentation approach
Martyn L Chilton, Donna S Macmillan, Thomas Steger-Hartmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 13, 2008
Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology
Nasser Hanna, Marcus Neubauer, Constantin Yiannoutsos, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 59) with videos related to
Sort By:
Page
of 6
Trials
|
July 28, 2012
What is the role and authority of gatekeepers in cluster randomized trials in health research?
Antonio Gallo, Charles Weijer, Angela White, et al.
Regulatory Toxicology and Pharmacology : RTP
|
October 25, 2025
Impurity qualification requirements for drug-linkers related impurities used to generate antibody-drug conjugates
Osama Chahrour, Paul D Cornwell, Penny Leavitt, et al.
Journal of Medical Internet Research
|
October 8, 2020
Experiences of Serving and Ex-Serving Members With the PTSD Coach Australia App: Mixed Methods Study
Jane Shakespeare-Finch, Karolina K Alichniewicz, Esben Strodl, et al.
Trials
|
July 28, 2011
Who is the research subject in cluster randomized trials in health research?
Andrew D McRae, Charles Weijer, Ariella Binik, et al.
Internet Interventions
|
September 17, 2020
Clinicians' perceptions of PTSD Coach Australia
Esben Strodl, Jane Shakespeare-Finch, Karolina K Alichniewicz, et al.
Regulatory Toxicology and Pharmacology : RTP
|
April 16, 2021
Use of less-than-lifetime (LTL) durational limits for nitrosamines: Case study of N-Nitrosodiethylamine (NDEA)
Joel P Bercu, Melisa Masuda-Herrera, George Johnson, et al.
Regulatory Toxicology and Pharmacology : RTP
|
August 7, 2021
Calculating qualified non-mutagenic impurity levels: Harmonization of approaches
Jessica C Graham, Mark W Powley, Erika Udovic, et al.
Regulatory Toxicology and Pharmacology : RTP
|
July 11, 2025
Evaluating the lifetime cumulative dose as a basis for carcinogenic potency of nitrosamines - a key tenet underpinning less-than-lifetime approaches for establishing acceptable intake limits
Susan P Felter, Ashley M Mudd, David J Ponting, et al.
Regulatory Toxicology and Pharmacology : RTP
|
March 28, 2018
Making reliable negative predictions of human skin sensitisation using an in silico fragmentation approach
Martyn L Chilton, Donna S Macmillan, Thomas Steger-Hartmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 13, 2008
Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology
Nasser Hanna, Marcus Neubauer, Constantin Yiannoutsos, et al.
Page
of 6